Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-87704916 in Advanced Solid Tumors
NCT06311578Phase 1Recruiting
- Sponsor
- Johnson & Johnson
- Start
- Apr 2024
- Primary completion
- Nov 2028
- Modality
- Oncolytic Viruses
- Countries
- 4
01
Overview
Phase 1, open-label trial of JNJ-87704916 in solid tumor and non-small cell lung cancer (NSCLC) (2 arms), sponsored by Johnson & Johnson. Primary endpoints: Dose-Limiting Toxicity up to 5 years and Adverse Events up to 5 years. Started Apr 2024; status: recruiting.
02
Drugs
JNJ-87704916
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06311578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06311578.